Systematic Review of Outcome Measures in Randomized Trials of Mediator-Directed Therapies in Sepsis

[1]  G. Guyatt,et al.  Outcome Measures: Methodologic Principles , 1997 .

[2]  J. Carlet,et al.  INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.

[3]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[4]  S. Willatts,et al.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.

[5]  J. Bertrand,et al.  Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. , 1996, Critical care medicine.

[6]  J. Dhainaut,et al.  CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. , 1995, Critical care medicine.

[7]  M. Boermeester,et al.  Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. , 1995, Archives of surgery.

[8]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[9]  S. Willatts,et al.  Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial. , 1995, Critical care medicine.

[10]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[11]  J. Dhainaut,et al.  Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial , 1994 .

[12]  C. Sprung,et al.  An evaluation of the hemodynamic effects of HA‐1A human monoclonal antibody , 1994, Critical care medicine.

[13]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[14]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[15]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[16]  G H Guyatt,et al.  USERS' GUIDES TO THE MEDICAL LITERATURE. II: HOW TO USE AN ARTICLE ABOUT THERAPY OR PREVENTION A. ARE THE RESULTS OF THE STUDY VALID ? , 1993 .

[17]  T. Clemmer,et al.  Detrimental effects of high‐dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock , 1993 .

[18]  C. Sprung,et al.  Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. , 1992, The Journal of infectious diseases.

[19]  N. Wedel,et al.  Observations using antiendotoxin antibody (E5) as adjuvant therapy in humans with suspected, serious, Gram‐negative sepsis , 1992, Critical care medicine.

[20]  M. Haupt,et al.  Effect of ibuprofen in patients with severe sepsis: A randomized, double‐blind, multicenter study , 1991, Critical care medicine.

[21]  G. Bernard,et al.  Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. , 1991, The American review of respiratory disease.

[22]  I. Schedel,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993 .

[23]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[24]  K. Dickersin.  The existence of publication bias and risk factors for its occurrence. , 1990, JAMA.

[25]  J. Schellekens,et al.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.

[26]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[27]  T. Clemmer,et al.  Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. , 1987, Chest.

[28]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[29]  Gaffin Sl.  Anti-endotoxin in the treatment of severe surgical septic shock. , 1986 .

[30]  C. Sprung,et al.  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.

[31]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[32]  L. Lindquist,et al.  Pepsin‐Treated Human Gamma Globulin in Bacterial Infections: A Randomized Study in Patients with Septicaemia and Pneumonia , 1981, Vox sanguinis.

[33]  D. Cook,et al.  Critical Evaluation of the Design and Conduct of Previous Clinical Trials in Sepsis , 1995 .

[34]  R. Bone,et al.  The Systemic Inflammatory Response Syndrome (SIRS) , 1995 .

[35]  J. Murray,et al.  Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. , 1990, The American review of respiratory disease.

[36]  R. Grundmann,et al.  Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis--a prospective randomized study. , 1988, Progress in clinical and biological research.